Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment

References

• Kipps T J. Chronic lymphocytic leukemia. Curr Opin Hematol 2000; 7: 223–234
   PubMed Web of Science ®Google Scholar
• Walunas T L, Lenschow D J, Bakker C Y, Linsley P S, Freeman G J, Green J M, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405–413
   PubMed Web of Science ®Google Scholar
• Grewal I S, Flavell R A. The CD40 ligand. At the center of the immune universe?. Immunol Res 1997; 16: 59–70
   PubMed Web of Science ®Google Scholar
• Mu X, Kay N E, Gosland M P, Jennings C D. Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells. Br J Haematol 1997; 96: 733–735
   PubMed Web of Science ®Google Scholar
• Hill S J, Peters S H, Ayliffe M J, Merceica J, Bansal A S. Reduced IL-4 and interferon-gamma (IFN-gamma) expression by CD4 T cells in patients with chronic lymphocytic leukaemia. Clin Exp Immunol 1999; 117: 8–11
   PubMed Web of Science ®Google Scholar
• Scrivener S, Goddard R V, Kaminski E R, Prentice A G. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003; 44: 383–389
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bergmann L, Karakas T, Mellstedt H, Osterborg A. Interleukin 4 therapy for patients with chronic lymphocytic leukaemia: a phase I/II study. Br J Haematol 2001; 112: 155–160
   PubMed Web of Science ®Google Scholar
• Rai K R, Peterson B L, Appelbaum F R, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757
   PubMed Web of Science ®Google Scholar
• Lundin J, Österborg A. Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia. Semin Hematol 2004; 41: 234–245
   PubMed Web of Science ®Google Scholar
• Österborg A, Mellstedt H, Keating M. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Med Oncol 2002; 19(Suppl)S21–S26
   PubMed Web of Science ®Google Scholar
• Keating M J, Flinn I, Jain V, Binet J L, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561
   PubMed Web of Science ®Google Scholar
• Rossmann E D, Lundin J, Lenkei R, Mellstedt H, Österborg A. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001; 2: 300–306
   PubMedGoogle Scholar
• Salisbury J R, Rapson N T, Codd J D, Rogers M V, Nethersell A B. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 1994; 47: 313–317
   PubMed Web of Science ®Google Scholar
• Österborg A, Werner A, Halapi E, Lundin J, Harmenberg U, Wigzell H, et al. Clonal CD8+ and CD52 – T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Eur J Haematol 1997; 58: 5–13
   PubMed Web of Science ®Google Scholar
• Rawstron A C, Rollinson S J, Richards S, Short M A, English A, Morgan G J, et al. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol 1999; 107: 148–153
   PubMed Web of Science ®Google Scholar
• Lundin J, Porwit-MacDonald A, Rossmann E D, Karlsson C, Edman P, Rezvany M R, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004; 18: 484–490
   PubMed Web of Science ®Google Scholar
• Hertenstein B, Wagner B, Bunjes D, Duncker C, Raghavachar A, Arnold R, et al. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood 1995; 86: 1487–1492
   PubMed Web of Science ®Google Scholar
• Coles A J, Wing M, Smith S, Coraddu F, Greer S, Taylor C, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691–1695
   PubMed Web of Science ®Google Scholar
• Bergmann L. Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Leukemia 1997; 11(Suppl 2)S29–S34
   PubMed Web of Science ®Google Scholar
• Fenchel K, Bergmann L, Wijermans P, Engert A, Pralle H, Mitrou P S, et al. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma 1995; 18: 485–492
   PubMed Web of Science ®Google Scholar
• Byrd J C, McGrail L H, Hospenthal D R, Howard R S, Dow N A, Diehl L F. Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Br J Haematol 1999; 105: 445–447
   PubMed Web of Science ®Google Scholar
• Takada K, Danning C L, Kuroiwa T, Schlimgen R, Tassiulas I O, Davis J C, Jr, et al. Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects. Ann Rheum Dis 2003; 62: 1112–1115
   PubMed Web of Science ®Google Scholar
• Anaissie E J, Kontoyiannis D P, O'Brien S, Kantarjian H, Robertson L, Lerner S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129: 559–566
   PubMed Web of Science ®Google Scholar
• Cheson B D. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431–2448
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Boyum A. Separation of lymphocytes, lymphocyte subgroups and monocytes: a review. Lymphology 1977; 10: 71–76
   PubMed Web of Science ®Google Scholar
• Mozaffari F, Hansson L, Kiaii S, Ju X, Rossmann E D, Rabbani H, et al. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 2004; 124: 315–324
   PubMed Web of Science ®Google Scholar
• Rossmann E D, Lewin N, Jeddi-Tehrani M, Österborg A, Mellstedt H. Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). Eur J Haematol 2002; 68: 299–306
   PubMed Web of Science ®Google Scholar
• Rezvany M R, Jeddi-Tehrani M, Rabbani H, Ruden U, Hammarstrom L, Osterborg A, et al. Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 2000; 111: 230–238
   PubMed Web of Science ®Google Scholar
• Österborg A, Dyer M J, Bunjes D, Pangalis G A, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567–1574
   PubMed Web of Science ®Google Scholar
• Wendtner C M, Ritgen M, Schweighofer C D, Fingerle-Rowson G, Campe H, Jager G, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093–1101
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003; 123: 380–388
   PubMed Web of Science ®Google Scholar
• Mellstedt H, Choudhury A. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother 2006; 55: 210–220
   PubMed Web of Science ®Google Scholar
• Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996; 26: 1308–1313
   PubMed Web of Science ®Google Scholar
• Carbone J E, Ohm D P. Immune dysfunction in cancer patients. Oncology (Huntingt) 2002; 16(Suppl 1)11–18
   PubMed Web of Science ®Google Scholar
• Elgert K D, Alleva D G, Mullins D W. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998; 64: 275–290
   PubMed Web of Science ®Google Scholar
• Thompson J A, Figlin R A, Sifri-Steele C, Berenson R J, Frohlich M W. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res 2003; 9: 3562–3570
   PubMed Web of Science ®Google Scholar
• Elflein K, Rodriguez-Palmero M, Kerkau T, Hunig T. Rapid recovery from T lymphopenia by CD28 superagonist therapy. Blood 2003; 102: 1764–1770
   PubMed Web of Science ®Google Scholar